市場概況

The dermatological therapeutics market is currently valued at USD 37.1 億で 2022 そして米ドルに達すると予測されています 65.3 10億まで 2028, 年複合成長率を示す (CAGR) の 9.67% 予測期間中.

The global economy and healthcare systems have faced significant challenges due to the high transmission rate of COVID-19. This has resulted in adverse effects on the manufacturing units of healthcare companies and disrupted transportation across developed and emerging markets. The dermatology market has also experienced both direct and indirect impacts from the pandemic. 例えば, a study published by PubMed Central in January 2021 revealed that the COVID-19 outbreak had a detrimental effect on most dermatology services, leading to a significant reduction in consultation time for chronic patients. 結果として, the market witnessed a significant impact on its growth. しかし, as the pandemic subsides, the dermatological therapeutics market is expected to regain stability and grow steadily during the forecast period.

例えば, according to the World Population Prospects 2022 Report, the share of the global population aged 65 years or above is projected to rise from 10% で 2022 に 16% で 2050. による 2050, the number of individuals aged 65 years and older worldwide is expected to be more than twice the number of children under the age of five and approximately the same as the number of children under the age of 12. This demographic shift towards an aging population is anticipated to contribute to the growth of the dermatological therapeutics market.

Skin diseases have a significant impact on people’s quality of life, leading to productivity loss at work and discrimination due to disfigurement. The Global Report on Atopic Dermatitis 2022 published by the International Eczema Council indicates that approximately 223 million people were living with atopic dermatitis in 2022, 周りと 43 million of them aged 1-4. This highlights the high prevalence of the disease in young children. In addition to the burden on children and their caregivers, atopic dermatitis can also adversely affect children’s development, 教育, and work. したがって, the high prevalence and increasing burden of dermatological diseases are expected to drive the growth of the market.

The dermatological therapeutics market is also expected to benefit from lucrative growth opportunities arising from collaborations, 買収, and new product launches. 例えば, 12月中 2021, LEO Pharma Inc. received approval from the US FDA for Adbry (tralokinumab-ldrm), an effective treatment for moderate-to-severe atopic dermatitis in adults who do not achieve adequate control with topical prescription therapies or for whom those therapies are not suitable.

The increasing burden of dermatological diseases, the rising elderly population, and advancements made by key market players are expected to drive the growth of the dermatological therapeutics market during the forecast period. しかし, serious side effects associated with certain therapeutic drugs may restrain the market in the near future.

市場セグメンテーション

市場はさまざまな要因に基づいて分割されます, including drug class, 応用, と地域.

Segmentation by Drug Class
Anti-infectives
Corticosteroids
Anti-acne
Calcineurin Inhibitors
Retinoids
Other Drug Classes

アプリケーションごとのセグメンテーション
Alopecia
Herpes
Psoriasis
Rosacea
Atopic Dermatitis
その他の用途

地域ごとのセグメンテーション
北米 – 米国とカナダ
ヨーロッパ – イギリス, ドイツ, フランス, スペイン, イタリア, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, インド, 韓国, オーストラリア, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, アルゼンチン, およびその他のラテンアメリカ諸国
中東とアフリカ – GCC, 南アフリカ, およびその他の中東およびアフリカ

The Psoriasis segment is expected to hold a significant market share over the forecast period. Psoriasis is a chronic autoimmune skin disease characterized by patches of thick red skin and silvery scales. The main type of psoriasis is plaque psoriasis, caused by misguided T-cell attacks on the skin. The growth of this segment is driven by several factors. There is a rising prevalence of psoriasis globally. According to the National Psoriasis Foundation, 約 125 million people worldwide had psoriasis in 2022, which accounts for around 2-3% of the total population. アメリカだけでも, より多い 8 million people were affected by psoriasis in 2022. This high prevalence is expected to increase the demand for dermatological therapeutics. さらに, the development of drugs for psoriasis through clinical trials is on the rise. 2月現在 2023, there were approximately 325 ongoing clinical trials globally focused on psoriasis treatment. These trials are expected to lead to future approvals of new treatments, thereby driving the growth of the psoriasis segment. The segment is fueled by new product launches, expanding market strategies of major market players, コラボレーション, そして買収. 例えば, the US FDA approved an expanded use of Amgen Inc.’s drug Otezla in December 2021 to treat adults with mild to moderate plaque psoriasis.

Considering the increasing prevalence of psoriasis, the growing geriatric population, the ongoing developments by key players, and the rising number of clinical trials, the psoriasis segment is expected to experience consistent growth throughout the forecast period.

North America is expected to have a significant market share in the dermatological therapeutics market. これにはいくつかの要因が考えられます. There is a notable increase in healthcare expenditure in North America, which contributes to a higher adoption rate of dermatological therapeutics. さらに, there is a growing awareness about skin diseases among the population, leading to increased demand for dermatological treatments. The strong presence of pharmaceutical companies in North America also plays a crucial role in driving the market. These companies are actively involved in new product launches and innovations in the field of dermatology, thereby boosting the market growth in the region. さらに, the prevalence of dermatological diseases, such as atopic dermatitis, is high in North America. 例えば, the Asthma and Allergy Foundation of America reported that around 16.5 million adults had atopic dermatitis, と 6.6 million experiencing moderate-to-severe symptoms in 2022. The rising geriatric population is another factor contributing to the growth of the market in the region.

Key market players in North America have been introducing new products in the market. 例えば, Sol-Gel Technologies Ltd received FDA approval for its proprietary drug product TWYNEO, indicated for the treatment of acne vulgaris. 同様に, Incyte gained FDA approval for Opzelura, a cream for the treatment of mild to moderate atopic dermatitis. These product launches further drive the market growth in North America. The North American market for dermatological therapeutics is expected to witness steady growth due to factors such as the rising prevalence of dermatological diseases, the increasing geriatric population, and the developments made by key market players. These factors contribute to the region’s significant market share over the forecast period.

競争環境

The dermatological therapeutics market exhibits a moderate level of fragmentation. This is attributed to the emergence of numerous new players who recognize the growth opportunities in this sector. The impending expiration of patents for major drugs has intensified competition, particularly in the generic segment, thus stimulating further growth in the market. The dermatological diagnostics and therapeutics industry is poised to experience significant expansion, with several generic players holding substantial market share, especially in developing regions. Among the prominent market players in this field are Amgen Inc., バウシュ ヘルス カンパニーズ Inc., ノバルティスAG, アッヴィ株式会社, and Almirall SA. These companies contribute to the competitive landscape and drive innovation in the field of dermatological therapeutics.

Key Companies Profiled in this report include Abbvie Inc., Aclaris Therapeutics Inc., アルミラル S.A., Amgen Inc., Aurobindo Pharma Limited, バウシュ ヘルス カンパニーズ Inc., ブリストル・マイヤーズ スクイブ社, イーライリリー アンド カンパニー, Galderma SA, GSK plc, Johnson and Johnson, Leo Pharma AS, ノバルティスAG, ファイザー株式会社, Sun Pharmaceutical Industries Ltd.

最近の業界の発展

9月中 2022, the United States Food and Drug Administration (FDA) granted approval to Sotyktu (deucravacitinib), an oral medication designed for adults diagnosed with moderate-to-severe plaque psoriasis and who are eligible for systemic therapy or phototherapy.

同様に, 7月に 2022, the FDA approved roflumilast cream (ZORYVE) 0.3%, a topical phosphodiesterase-4 (PDE4) inhibitor, as a treatment option for plaque psoriasis among patients aged 12 years and above.

さらに, 1月に 2022, Abbvie made an announcement regarding the FDA’s approval of Rinvoq. This approval allows Rinvoq to be prescribed for individuals aged 12 years and older who have refractory, moderate-to-severe atopic dermatitis and have not responded to or cannot take previous oral or injectable systemic medications.

主な質問への回答

この市場分析の調査期間はどれくらいですか??
What is the rate of growth in the Dermatological Therapeutics Market?
What was the size of the Dermatological Therapeutics Market in 2018?
What is the projected size of the Dermatological Therapeutics Market in 2028?
Which region demonstrates the highest growth rate in the Dermatological Therapeutics Market?
Which region holds the largest market share in the Dermatological Therapeutics Market?
Who are the major players in the Dermatological Therapeutics Market?